Malignant rhabdoid tumor of soft tissues: A cytopathological and immunohistochemical study

1992 ◽  
Vol 8 (4) ◽  
pp. 369-373 ◽  
Author(s):  
J. Sola Pérez ◽  
M. Pérez-Guillermo ◽  
A. Bas Bernal ◽  
T. Manzanera López ◽  
F. Caro López
2010 ◽  
Vol 18 (2) ◽  
pp. 150-158 ◽  
Author(s):  
Isidro Machado ◽  
Rosa Noguera ◽  
Nuria Santonja ◽  
Joaquín Donat ◽  
Rafael Fernandez-Delgado ◽  
...  

2006 ◽  
Vol preprint (2007) ◽  
pp. 1
Author(s):  
Henry Krous ◽  
Amy Chadwick ◽  
Elisabeth Haas ◽  
Eric Breisch ◽  
Homeyra Masoumi

2006 ◽  
Vol preprint (2007) ◽  
pp. 1
Author(s):  
Lars Wagner ◽  
Jennifer Garrett ◽  
Edgard Ballard ◽  
D. Hill ◽  
Arie Perry ◽  
...  

2021 ◽  
pp. 109352662098649
Author(s):  
Tiffany G Baker ◽  
Michael J Lyons ◽  
Lee Leddy ◽  
David M Parham ◽  
Cynthia T Welsh

Rhabdoid tumor predisposition syndrome (RTPS) is defined as the presence of a SMARCB1 or SMARCA4 genetic aberration in a patient with malignant rhabdoid tumor. Patients with RTPS are more likely to present with synchronous or metachronous rhabdoid tumors. Based on the current state of rhabdoid tumor taxonomy, these diagnoses are based largely on patient demographics, anatomic location of disease, and immunohistochemistry, despite their nearly identical histologic and immunohistochemical profiles. Thus, the true distinction between such tumors remains a diagnostic challenge. Central nervous system atypical teratoid/rhabdoid tumor (AT/RT) is a rare, aggressive, primarily pediatric malignancy with variable histologic features and a well documented association with loss of SMARCB1 expression. Epithelioid sarcoma (ES) is a rare soft tissue tumor arising in patients of all ages and characteristically staining for both mesenchymal and epithelial immunohistochemical markers while usually demonstrating loss of SMARCB1 expression. To our knowledge we herein present the first documented case of a patient with RTPS who presented with metachronous AT/RT and ES.


2021 ◽  
Vol 16 (4) ◽  
pp. 815-818
Author(s):  
Dasic Ivana ◽  
Cvejic Sofija ◽  
Pavicevic Polina ◽  
Rancic Smilja

2014 ◽  
Vol 207 (9) ◽  
pp. 415-419 ◽  
Author(s):  
Kristopher R. Bosse ◽  
Aseem R. Shukla ◽  
Bruce Pawel ◽  
Kudakwashe R. Chikwava ◽  
Mariarita Santi ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Adel Attia ◽  
Moosa Suleman ◽  
Hesham Mosleh

Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal malignancies in pediatric oncology. Malignant rhabdoid tumor was initially described in 1978 as a rhabdomyosarcomatoid variant of a Wilms tumor because of its occurrence in the kidney and because of the resemblance of its cells to rhabdomyoblasts. The absence of muscular differentiation led Haas and colleagues to coin the term rhabdoid tumor of the kidney in 1981, Haas et al..


2003 ◽  
Vol 194 (3) ◽  
pp. 303-313 ◽  
Author(s):  
Britta S. Reincke ◽  
Gary B. Rosson ◽  
Betty W. Oswald ◽  
Cynthia F. Wright

Sign in / Sign up

Export Citation Format

Share Document